8-K current report · filed Nov 12, 2026

Parabilis Medicines Inc (PBLS) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1PBLS overview

Short answer

Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended September 30, 2026 results announced.

Parabilis Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced
  • Press release includes Parabilis Medicines’ financial results and business highlights
  • Exhibit 99.1 contains the detailed quarterly financial information and investor-relevant updates

Item EX-99.1 · Exhibit EX-99.1

  • Zolucatetide desmoid-tumor data: 72.2% ORR at 32 weeks, 100% DCR across 46 patients, with no treatment-related discontinuations
  • FDA-aligned PEDESTAL Phase 3 design, planned launch in first half 2027 and topline results anticipated in 2029
  • Cash, equivalents and marketable securities $1.1B, expected to fund operations into 2030, reducing near-term financing risk
  • Third-quarter revenue $2.1M, R&D expense $45.6M, and net loss $44.5M, reflecting accelerating clinical investment
  • Revolution Medicines collaboration adds a combination study in previously treated RAS G12D-mutant MSS CRC, with costs shared equally

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Parabilis Medicines Inc 8-K filings

Get the next PBLS 8-K as it lands

Follow PBLS for push alerts, or ask the research agent what this filing means.